PROactive
The PROactive project is a European project funded by the Innovative Medicines Initiative (IMI). IMI is a Joint Initiative (JI) funded by both the EC (via the FP7 research programme) and EFPIA. Under this initiative, the PROactive consortium aims to improve care for COPD patients. The consortium includes 19 partners (academic institutions, a small-to-medium sized enterprise, patient organisations and eight major pharmaceutical companies).
PROactive, as part of the European Innovative Medicines Initiative (IMI), is a project that aims to develop, validate and use patient reported outcome (PRO) tools investigating dimensions of physical activity that are judged by patients living with chronic obstructive pulmonary disease (COPD) to be essential. A better understanding of all relevant dimensions (amount, symptoms, distress, etc.) of physical (in)activity that are meaningful to patients will help to describe the patients' experience of COPD in a more insightful manner and help refine the armamentarium of patient management tools. Improvement on the PROs will offer new end-points for clinical trials and labelling. The PROs will be developed with input from the regulatory authorities.
The PROactive Consortium)
PROactive consortium members attending the 2011 General Assembly meeting in June in Barcelona
The PROactive project aims to develop validation and use of patient reported outcome (PRO) tools to investigate dimensions of physical activity that are judged as being essential by patients living with COPD. A better understanding of all relevant dimensions (symptoms, distress, etc.) of physical activity that are meaningful to COPD patients will help describe the patients' experience of COPD. PROactive will be developed with input from the regulatory authorities, such as the European Medicines Agency (EMA). Once appropriately validated, PROactive will be used to evaluate the benefit of new treatments such as new medicinal products for COPD patients.
